Familiarity breeds contempt: The Tipline for 23 January 2023

The Federal Trade Commission and former pharmaceutical executive Martin Shkreli have gotten to know each other very well over the years. Whether sparring over jacking up the price of a life-saving drug by 4,000% or illegally conducting business from prison with a contraband phone, the commission and “Pharma Bro” go together like toothpaste and orange juice. Their latest collaboration? The FTC has asked that Shkreli be held in contempt for forming a new company while failing to pay a penny of the $64.6 million he owes in equitable relief.

Unlock unlimited access to all Global Competition Review content